Lisa A. Raedler
- Oncology top 10%
- Molecular Biology
- Immunology
- Genetics top 10%
- Hematology top 10%
- Topics
- Chronic Lymphocytic Leukemia Research (10 papers)Chronic Myeloid Leukemia Treatments (7 papers)Multiple Myeloma Research and Treatments (6 papers)
- Cited by
- OncologyGeneticsImmunology
- Journals
- PubMedPubMed Central
In The Last Decade
Lisa A. Raedler
50 papers receiving 637 citations
Peers
Comparison fields: 5 of 85
- Oncology 307
- Molecular Biology 185
- Immunology 150
- Genetics 95
- Hematology 79
Countries citing papers authored by Lisa A. Raedler
This map shows the geographic impact of Lisa A. Raedler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa A. Raedler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa A. Raedler more than expected).
Fields of papers citing papers by Lisa A. Raedler
This network shows the impact of papers produced by Lisa A. Raedler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa A. Raedler. The network helps show where Lisa A. Raedler may publish in the future.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults | 1 |
| 2 | Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 1 |
| 3 | Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma. | 7 |
| 4 | Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. | 23 |
| 5 | Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia. | 13 |
| 6 | Cabometyx (Cabozantinib) Tablets First Multikinase Inhibitor Approved for the Treatment of Patients with Advanced Renal-Cell Carcinoma | 1 |
| 7 | Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma | 3 |
| 8 | Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma | 2 |
| 9 | Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia. | 14 |
| 10 | Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia | 3 |
| 11 | Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma. | 5 |
| 12 | Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma. | 63 |
| 13 | Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea. | 11 |
| 14 | Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. | 39 |
| 15 | Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma | 1 |
| 16 | Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes. | 8 |
| 17 | Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia. | 10 |
| 18 | Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil | 1 |
| 19 | Gilotrif: Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation | 1 |
| 20 | Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer | 2 |
About Lisa A. Raedler
Lisa A. Raedler is a scholar working on Hematology, Genetics and Oncology, having authored 53 papers that have together received 649 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Multiple Myeloma Research and Treatments (6 papers). The work is most often cited by research in Oncology (307 citations), Genetics (95 citations) and Immunology (150 citations). Their work appears in journals such as PubMed and PubMed Central.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.